Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cyclo Therapeutics, Inc. - Common Stock (NQ:CYTH)

0.7206 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.7206
Bid (Size) 0.6800 (5)
Ask (Size) 0.7199 (20)
Prev. Close 0.7206
Today's Range 0.7206 - 0.7206
52wk Range 0.5700 - 1.450
Shares Outstanding 28,715,740
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the... 
From Rafael Holdings, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga

Performance

YTD
+20.1%
+20.1%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+9.2%
+9.2%
1 Year
-42.4%
-42.4%

More News

Read More
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
From Kahn Swick & Foti, LLC
Via Business Wire
Which stocks are experiencing notable movement on Monday?
Via Chartmill
Monday's pre-market session: top gainers and losers
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
From Cyclo Therapeutics, Inc.
Via Business Wire
Cyclo Therapeutics to Present at the 21st Annual WORLDSymposium™ 2025
From Cyclo Therapeutics, Inc.
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, FLIC, ARCH, CYTH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ZUO, ARCH, CYTH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USAP, CYTH, ARCH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Cyclo Therapeutics, Inc.
Via Business Wire
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
From Rafael Holdings, Inc.
Via GlobeNewswire
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
From Pacira BioSciences
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
From Brodsky & Smith LLC
Via GlobeNewswire
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1)
From Cyclo Therapeutics
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)
From Brodsky & Smith LLC
Via GlobeNewswire
This Hershey Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
From Kahn Swick & Foti, LLC
Via Business Wire

Frequently Asked Questions

Is Cyclo Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cyclo Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cyclo Therapeutics, Inc. - Common Stock trade on?
Cyclo Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cyclo Therapeutics, Inc. - Common Stock?
The ticker symbol for Cyclo Therapeutics, Inc. - Common Stock is CYTH on the Nasdaq Stock Market
What is the current price of Cyclo Therapeutics, Inc. - Common Stock?
The current price of Cyclo Therapeutics, Inc. - Common Stock is 0.7206
When was Cyclo Therapeutics, Inc. - Common Stock last traded?
The last trade of Cyclo Therapeutics, Inc. - Common Stock was at 03/25/25 04:00 PM ET
What is the market capitalization of Cyclo Therapeutics, Inc. - Common Stock?
The market capitalization of Cyclo Therapeutics, Inc. - Common Stock is 20.69M
How many shares of Cyclo Therapeutics, Inc. - Common Stock are outstanding?
Cyclo Therapeutics, Inc. - Common Stock has 21M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.